Rep. Spanberger Issues Statement on Johnson & Johnson Suspending Plan to Stop Direct Drug Discounts for Hospitals in Underserved Communities
October 01, 2024
October 01, 2024
WASHINGTON, Oct. 1 -- Rep. Abigail Spanberger, D-Virginia, issued the following statement on Sept. 30, 2024:
* * *
U.S. Representative Abigail Spanberger today released the following statement after Johnson & Johnson (J&J) suspended the company's plan to transition two lifesaving drugs currently available at a direct discount under the 340B Drug Pricing Program to an unapproved rebate model.
"The 340B program -- which was created by Congre . . .
* * *
U.S. Representative Abigail Spanberger today released the following statement after Johnson & Johnson (J&J) suspended the company's plan to transition two lifesaving drugs currently available at a direct discount under the 340B Drug Pricing Program to an unapproved rebate model.
"The 340B program -- which was created by Congre . . .